S C I E N T I F I C I N V E S T I g A T I O N S
C hanges in weight are inextricably linked to obstructive sleep apnea (OSA). 1 Weight gain is a risk for both the development and increased severity of OSA. 2 Conversely, weight loss may result in remission or improvement in OSA. 3 In one review, it has been estimated that 58% of OSA can be attributable to excess weight. 4 There also is evidence that OSA itself contributes to weight gain, [5] [6] [7] thus creating an adverse positive feedback loop whereby increasing weight leads to OSA, and OSA results in further weight gain. Treatment of OSA with continuous positive airway pressure (CPAP) should therefore prevent further weight gain or facilitate weight loss. However, available evidence is confl icting, with two studies demonstrating CPAP users losing weight 8, 9 while others observed either no change or increases in weight. [11] [12] [13] [14] [15] However, these studies have been retrospective, small in size, lacked a parallel control group, or were not blinded. Thus, it is unclear whether treatment of OSA with CPAP results in any changes in weight.
The Apnea Positive Pressure Long-term Effi cacy Study (APPLES) was a 6-month randomized controlled clinical trial to determine the impact of CPAP or Sham CPAP on a variety of neurocognitive outcomes in persons with OSA. 16 As part of this study, weight measurements at the baseline and follow-up study visits were included in the protocol. Thus, APPLES is an 
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Current knowledge/Study Rationale: Obese OSA patients commonly believe that treatment with CPAP will facilitate weight loss. However, empirical observations and uncontrolled studies suggest otherwise. Data from randomized controlled studies are lacking. Study Impact: In this 6 month randomized controlled trial, treatment with CPAP resulted in weight gain, not weight loss. Therefore, in addition to treatment with CPAP, obese OSA patients should engage in other behaviors such as increased physical activity and reduction in caloric intake to lose weight.
Women's Hospital, Boston, MA. The institutional review board (IRB) at each site approved the study protocol. Enrollment began in November 2003 and was completed in August 2008. All participants were adults with age ≥ 18 years and with an apnea hypopnea index (AHI) ≥ 10 events per hour. Excluded were individuals who had (1) prior OSA treatment with CPAP or surgery, (2) household members with current/past CPAP use, (3) a sleepiness-related automobile accident within the year prior to potential enrollment, (4) oxygen saturation < 75% for > 10% of the diagnostic polysomnogram (PSG) total sleep time; or (5) conditions or use of medications that could potentially affect neurocognitive function and/or alertness. For this analysis, only participants who had been randomized and had valid weight measurements at baseline and at the 6-month time point are included.
Study Design
The APPLES protocol has been described in detail elsewhere. 16 In brief, participants were recruited from sleep clinics and by public advertisement. If an initial interview determined that there were no exclusion criteria, consenting participants underwent diagnostic PSG as previously described. 16 Those who had an AHI ≥ 10/h and were not excluded because of severe oxygen desaturation were randomized to either active or sham CPAP (REMStar Pro, Phillips Respironics, Murrysville, PA) for 6 months. For those randomized to CPAP, the therapeutic pressure was determined during a sleep laboratory titration following their initial PSG. Those randomized to Sham underwent a sham PSG titration in the sleep laboratory. Neurocognitive assessments, the primary focus of the study, were performed at baseline and 2 and 6 months afterwards. The Epworth Sleepiness Scale was a component of the neurocognitive assessments. At these visits, weight measurements also were obtained using calibrated balance beam or digital scales, with the participant in street clothes without shoes. The same scale type was used at each visit. Height was measured at baseline using a stadiometer. Adherence to treatment was assessed objectively using Encore Pro SmartCards (Philips Respironics, Inc., Murrysville, PA), which were returned twice monthly.
Statistical Analyses
Body mass index (BMI) was computed as weight (kg)/height (m) 2 . Participants' race/ethnicity were classified as self-reported white or non-white. Assessment of adherence to CPAP or Sham used data obtained during the 1 month prior to the 6-month visit and was expressed as the mean hours of nightly use. Classification of participants as adherent or non-adherent was based on whether they used their assigned treatment > 4 h on ≥ 70% of nights. For continuous variables, unadjusted comparisons between CPAP and Sham were made using Students' t-test. Differences in proportions were assessed using the χ 2 test. Repeated measures analysis of variance and covariance and linear regression were used to determine the impact of treatment group as well as other possible factors on weight change over the 6-month timeframe of the study. Data are expressed as mean ± standard deviation (SD) or percentages. Analyses were performed using IBM SPSS Statistics Version 20 (Chicago, IL).
RESULTS
There were 1,105 participants initially randomized, but 7 were later excluded because they were later found to be ineligible or inadvertently received both study arms. Another 286 were excluded for missing measurements of body weight at 6 months. Of the remaining 812 participants, 387 had been randomized to Sham and 425 to active CPAP. There were no differences in baseline weight, height, gender, race, AHI, or ESS between participants with and without 6-month weight measurements. However, participants who had 6-month weight data were slightly older (52.5 ± 12.2 vs. 48.9 ± 12.4 years, p < 0.001). As shown in Table 1 , participants generally were middle-aged, white, male, and obese. They also had moderate to severe OSA, were mildly sleepy, and had suboptimal adherence to their assigned treatment. There were no differences between the 2 groups with respect to age, gender, race, OSA severity, weight, BMI, or Epworth Sleepiness Scale score. However, participants in the Sham group were generally less adherent to their assigned treatment.
The changes in weight from baseline to the 6-month time point for the Sham and CPAP groups are shown in Figure 1 . Participants in the Sham group had a slight decrease in their weight, whereas those in the CPAP group had a slight increase. This difference in weight change was statistically significant (Sham = -0.70 ± 4.03 vs CPAP = 0.35 ± 5.01 kg, p = 0.001).
There was no effect modification related to age, gender, race, baseline BMI, OSA severity, or ESS score, and these factors were not included in subsequent analytic models. However, change in weight was associated with adherence in the CPAP group, with each hour per night of CPAP use associated with a mean 0.42 kg increase in weight over 6 months (p = 0.001). In contrast, there was no association between weight change and adherence in the Sham group. Table 2 shows mean baseline and 6-month weights stratified by treatment group and treatment adherence. There were 707 participants with analyzable adherence data. When classified by whether participants had 70% of nights with > 4 hours use, strikingly, adherent CPAP participants had a mean 1 kg increase in weight (97.0 ± 20.1 vs. 98.0 ± 25.6 kg, p = 0.014). In contrast, non-adherent Sham participants had a slight decrease in weight (96.3 ± 21.7 vs. 95.6 ± 21.7, p = 0.008).
DISCUSSION
In this study we found that treatment of OSA with CPAP did not result in a reduction in weight, and actually was associated with weight gain. This observation was independent of age, gender, race, OSA severity, and sleepiness. Furthermore, those with the greatest adherence to CPAP appeared to have gained the most weight.
The primary finding in this study is that CPAP treatment of OSA does not result in weight loss over a 6-month time frame. Our findings are therefore consistent with those of Redenius et al., who failed to observe in a retrospective study any reduction in weight in 183 CPAP treated patients followed in a sleep center over 10 to 14 months. 12 Similarly, several smaller studies also have failed to find a change in weight with CPAP treatment. In a randomized controlled trial of sibutramine in comparison to CPAP for weight loss, CPAP treatment for one year in 18 patients was not associated with a change in weight.
11 Similarly, addition of CPAP did not result in greater weight loss when used as adjunctive therapy for a behavioral weight loss program in OSA patients. 15 In two other randomized controlled studies of CPAP compared to sham CPAP, CPAP treatment for 12 weeks or 24 weeks also did not result in weight loss. 13, 14 However, the latter four studies may have been inadequately powered to detect a small change in weight. In a much larger, although non-blinded randomized study, CPAP treatment for a median of four years failed to result in weight loss. 10 In contrast, Loube et al. observed that in 21 CPAP-treated OSA patients, those who self-reported being adherent were more likely to have greater than a 4.5 kg weight loss than those non-adherent. However, there was no significant weight change for the group overall. 9 More recently, Sharma and colleagues in a randomized crossover design of 86 participants found that CPAP treatment for 3 months resulted in a mean weight loss of 0.37 kg compared to a 0.33 kg weight gain with sham CPAP. 8 Our study of 812 participants is considerably larger than all but one of the aforementioned investigations and would be more likely to detect small changes in weight. Thus our results do not support the hypothesis that CPAP treatment of OSA facilitates weight loss.
We observed that aside from adherence to treatment assignment, no other factors modified the association between CPAP (or sham CPAP) and change in weight. In contrast, Redenius et al. found that women were more likely to gain weight after CPAP use. 12 However, their data were derived retrospectively from a clinical population, whereas APPLES participants were largely recruited from the community. Thus, participant characteristics may account for this different observation.
In our study, participants treated with CPAP not only failed to lose weight, but actually appeared to gain a small amount of weight. Moreover, we found that those who were adherent to CPAP gained weight over six months of therapy in contrast to no significant weight increase observed in the sham or nonadherent CPAP participants. Furthermore, there was a dose response relationship between hours of adherence and amount of weight gained. These findings are consistent with Redenius et al., who found that in a subgroup analysis, those who used CPAP for more than 7 hours per night on 90% of nights had an increase in their BMI.
12 Furthermore, in a small randomized controlled study, Garcia et al. observed a small amount of weight gain in 20 obese OSA subjects over the course of 6 months. 13 Our study extends these latter findings by documenting weight gain with CPAP in a much larger cohort and showing that it is a function of adherence. Thus, our findings and those of previous studies suggest that CPAP is inducing a state of positive energy balance resulting in weight gain.
There are several mechanisms related to energy expenditure (EE) that could explain why persons treated with CPAP gain weight. Weight gain occurs when energy intake (EI) exceeds EE. Some but not all studies indicate that resting 24-hour as well as sleep EE in persons with OSA are higher than in those without OSA. 17, 18 Furthermore, EE may be higher in those with greater severity of OSA.
19 Elevated EE during sleep in OSA patients may be related to greater work of breathing, similar to that observed in patients with chronic obstructive lung disease. 20, 21 Alternatively, there may be greater activation of the sympathetic nervous system as a result of more frequent arousals and intermittent hypoxia. 22 Intervention with CPAP as well as upper airway surgery has been shown to reduce sleep EE, and in the absence of change in energy intake would favor weight gain. 17, 18, 23 Alterations in level of physical activity and dietary habits with CPAP also could change the balance between EI and EE in OSA. Although patients with OSA often indicate that sleepiness and lack of energy are barriers to increased physical activity, a recent study observed that intervention with CPAP for three months improved sleepiness but did not alter activity levels. 24 Inflammatory cytokines are elevated in OSA and decrease with use of CPAP. 25, 26 They may promote anorexia, 27 and thus CPAP might reduce this effect leading to weight gain. However, we have previously demonstrated in APPLES that OSA participants eat high-caloric atherogenic diets. 28 Preliminary data from a four-month follow-up of these participants indicate that their dietary habits do not change after intervention with CPAP. 29 Thus, available evidence suggests that CPAP reduces sleep EE, but there is no corresponding increase in daytime EE or decrease in EI. This results in an energy balance that favors weight gain.
Fluid retention related to elevations in intrathoracic pressure from CPAP could explain some of the weight gain. In both clinical and experimental studies, positive airway pressure results in fluid retention related to a reduction in venous return and decreased secretion of antidiuretic hormone and atrial natriuretic peptide. 30, 31 However, any contribution from fluid retention is likely to be minor because CPAP is not used during wakefulness in OSA.
Our study is not without limitations. First, overall adherence to both treatment arms was suboptimal. However, the levels of adherence in this study are similar to those in other long-term randomized controlled trials. 13, 14, 32 Furthermore, given our current findings, greater adherence would likely have made the differences in weight between CPAP and Sham even more striking. Second, in comparison to the CPAP group, more participants in the Sham group failed to complete the study. Differential dropout of Sham participants who were more likely to gain weight might explain the difference between the two groups, although there is no evidence that this occurred. Third, because the primary focus of this study was on neurocognitive outcomes, we did not collect data such as direct energy expenditure measurements, which might validate proposed mechanisms underlying the increase in weight observed in CPAP participants. Lastly, most of our participants were recruited from the community and not a sleep clinic. Thus, our findings may not be representative of the patient population seen in a clinical setting. Despite these limitations, our study had a number of strengths, including the large number of participants, a long 6-month follow-up period, use of sham CPAP as a control, and objective documentation of adherence to therapy.
In conclusion, treatment of OSA with CPAP may result in modest weight gain. Thus, if overweight, OSA patients should be encouraged to lose weight by other modalities and not rely on any direct physiologic effect of CPAP.
